IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA

被引:237
作者
ABIGERGES, D
ARMAND, JP
CHABOT, GG
DACOSTA, L
FADEL, E
COTE, C
HERAIT, P
GANDIA, D
机构
[1] INST GUSTAVE ROUSSY,DEPT ADULT MED,F-94805 VILLEJUIF,FRANCE
[2] LAB ROGER BELLON,NEUILLY SUR SEINE,FRANCE
关键词
D O I
10.1093/jnci/86.6.446
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Diarrhea is a serious side effect that may prevent the administration of high doses of the antitumor drug Irinotecan (CPT-11). Purpose: Intensive, high-dose loperamide was used in an attempt to control or downstage CPT-11-induced diarrhea and thus permit the use of higher dose intensities of CPT-11. Methods: Twenty-three patients with various cancers were treated with doses of CPT-11 ranging from 400 to 600 mg/m(2), administered as a 30-minute intravenous infusion every 3 weeks. Starting 8 hours or more after the administration of CPT-11, any episode of diarrhea was treated with 2 mg of loperamide taken every 2 hours. Patients stopped taking loperamide only after a 12-hour diarrhea-free period. If diarrhea was not controlled after 3 consecutive days of nonstop loperamide intake, or if the patient was dehydrated, loperamide was stopped and the patient was hospitalized for intravenous fluids. If blood or mucus were found in the stools at any time during diarrhea, loperamide was stopped and the patient was hospitalized. Results: Seventeen of 23 patients had diarrhea while on CPT-11 treatment. Eighty-two CPT-11 cycles were administered to these 17 patients, and diarrhea occurred in 49 of these cycles, at a median time-to-onset of 6 days after CPT-11 administration. The loperamide protocol was followed in 46 of the 49 episodes of diarrhea, with 21 capsules of loperamide the median number being taken (range, 5-72). Only one patient was hospitalized for failure to respond to loperamide, and no major toxicity was associated with loperamide use. Fourteen of the 17 patients who experienced diarrhea were rechallenged with CPT-11 three or more times, and seven patients six or more times. Conclusions: High-dose loperamide controlled diarrhea in patients receiving CPT-11 and allowed administration of higher doses of,CPT-ll. Implications: The effectiveness of CPT-11 might be increased by higher dose intensities, which can be made tolerable by control of diarrhea with loperamide.
引用
收藏
页码:446 / 449
页数:4
相关论文
共 8 条
  • [1] BURRIS HA, 1992, SEMIN ONCOL, V19, P663
  • [2] CHEN G, 1951, J PHARMACOL EXP THER, V103, P330
  • [3] CPT-11-INDUCED CHOLINERGIC EFFECTS IN CANCER-PATIENTS
    GANDIA, D
    ABIGERGES, D
    ARMAND, JP
    CHABOT, G
    DACOSTA, L
    DEFORNI, M
    MATHIEUBOUE, A
    HERAIT, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 196 - 197
  • [4] LOPERAMIDE - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN DIARRHEA
    HEEL, RC
    BROGDEN, RN
    SPEIGHT, TM
    AVERY, GS
    [J]. DRUGS, 1978, 15 (01) : 33 - 52
  • [5] ABUSE POTENTIAL OF LOPERAMIDE
    JAFFE, JH
    KANZLER, M
    GREEN, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (06) : 812 - 819
  • [6] PHASE-I STUDY AND PHARMACOKINETICS OF CPT-11 WITH 5-DAY CONTINUOUS INFUSION
    OHE, Y
    SASAKI, Y
    SHINKAI, T
    EGUCHI, K
    TAMURA, T
    KOJIMA, A
    KUNIKANE, H
    OKAMOTO, H
    KARATO, A
    OHMATSU, H
    KANZAWA, F
    SAIJO, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (12) : 972 - 974
  • [7] AN EARLY PHASE-II STUDY OF CPT-11 - A NEW DERIVATIVE OF CAMPTOTHECIN, FOR THE TREATMENT OF LEUKEMIA AND LYMPHOMA
    OHNO, R
    OKADA, K
    MASAOKA, T
    KURAMOTO, A
    ARIMA, T
    YOSHIDA, Y
    ARIYOSHI, H
    ICHIMARU, M
    SAKAI, Y
    OGURO, M
    ITO, Y
    MORISHIMA, Y
    YOKOMAKU, S
    OTA, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) : 1907 - 1912
  • [8] ROWINSKY E, 1992, P AN M AM SOC CLIN, V11, P115